Mural Oncology Plc Completes Acquisition by XRA 5 Corp.

Mural Oncology Plc ( (MURA) ) just unveiled an update.

On December 5, 2025, Mural Oncology Plc announced the completion of its acquisition by XRA 5 Corp., a subsidiary of XOMA Royalty Corporation, through a scheme of arrangement. Following the acquisition, Mural’s shares were delisted from Nasdaq, and shareholders will receive cash consideration by December 19, 2025. This strategic move signifies a significant shift in Mural’s market positioning and operational structure, impacting its stakeholders and aligning with XOMA Royalty’s business objectives.

The most recent analyst rating on (MURA) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Mural Oncology Plc stock, see the MURA Stock Forecast page.

Spark’s Take on MURA Stock

According to Spark, TipRanks’ AI Analyst, MURA is a Neutral.

Mural Oncology Plc’s stock is weighed down by its financial challenges, including zero revenue and high cash burn, which significantly impact its overall score. Technical indicators suggest some positive momentum, but the stock faces resistance. Valuation remains unattractive due to unprofitability. However, upcoming clinical milestones and strategic focus on efficiency provide potential upside, reflected in the corporate events score.

To see Spark’s full report on MURA stock, click here.

More about Mural Oncology Plc

Mural Oncology Plc operates in the biotechnology sector, focusing on oncology treatments and therapies. The company is involved in developing innovative cancer treatment solutions and has been listed on the Nasdaq Global Market.

Average Trading Volume: 170,829

Technical Sentiment Signal: Strong Sell

Current Market Cap: $35.38M

For a thorough assessment of MURA stock, go to TipRanks’ Stock Analysis page.